• 1.

    den Boer M, Argaw D, Alvar J, 2011. Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 14711477.

  • 2.

    Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366: 15611577.

  • 3.

    Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.

  • 4.

    Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, 2008. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 105: 19.

  • 5.

    Goto H, Angelo J, Lindoso L, 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419433.

    • Search Google Scholar
    • Export Citation
  • 6.

    Blum JA, Hatz CF, 2009. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 16: 123131.

  • 7.

    Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE, 2004. Old World leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 39: 16741680.

    • Search Google Scholar
    • Export Citation
  • 8.

    Pavli A, Maltezou HC, 2010. Leishmaniasis: an emerging infection in travelers. Int J Infect Dis 14: e1032e1039.

  • 9.

    Stark D, van Hal S, Lee R, Marriott D, Harkness J, 2008. Leishmaniasis, an emerging imported infection: report of 20 cases from Australia. J Travel Med 15: 351354.

    • Search Google Scholar
    • Export Citation
  • 10.

    Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, Lockwood DNJ, 2004. New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. Q J Med 97: 781788.

    • Search Google Scholar
    • Export Citation
  • 11.

    Harms G, Schonian G, Feldmeier H, 2003. Leishmaniasis in Germany. Emerg Infect Dis 9: 872875.

  • 12.

    Alvar J, Aparicio P, Aseffa A, den Boer M, Canavate C, Dedet J-P, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.

    • Search Google Scholar
    • Export Citation
  • 13.

    Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M, 2008. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 8: 191199.

  • 14.

    Zanger P, Kotter I, Kremsner PG, Gabrysch S, 2011. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect, doi: 10.1111/j.1469-0691.2011.03674.x.

    • Search Google Scholar
    • Export Citation
  • 15.

    Herwaldt BH, 2001. Laboratory-acquired parasitic infection from accidental exposures. Clin Microbiol Rev 14: 659688.

  • 16.

    McHugh CP, Melby PC, LaFon SG, 1996. Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. Am J Trop Med Hyg 55: 547555.

    • Search Google Scholar
    • Export Citation
  • 17.

    Cardo LJ, 2006. Leishmania: risk to the blood supply. Transfusion 46: 16411645.

  • 18.

    Croft S, Olliaro P, 2011. Leishmaniasis chemotherapy—challenges and opportunities. Clin Microbiol Infect 17: 14781483.

  • 19.

    Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.

    • Search Google Scholar
    • Export Citation
  • 20.

    Berman J, 2008. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 4: 12091216.

  • 21.

    Davidson RN, den Boer M, Ritmeijer K, 2008. Paromomycin. Trans R Soc Trop Med Hyg 103: 653660.

  • 22.

    Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zaatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grogl M, 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 5: e423.

    • Search Google Scholar
    • Export Citation
  • 23.

    Gonzalez GU, Pinart M, Rengifo-Pardo M, Alvar J, Tweed JA, 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2: CD004834.

    • Search Google Scholar
    • Export Citation
  • 24.

    Gonzalez U, Pinart M, Reveiz L, Alvar J, 2008. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 8: CD005067.

  • 25.

    Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MML, 2011. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis. Clin Infect Dis 53: 693695.

    • Search Google Scholar
    • Export Citation
  • 26.

    Meyerhoff A, 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28: 4248.

    • Search Google Scholar
    • Export Citation
  • 27.

    Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.

    • Search Google Scholar
    • Export Citation
  • 28.

    Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350356.

    • Search Google Scholar
    • Export Citation
  • 29.

    Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A, 2010. Liposomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 83: 10281033.

    • Search Google Scholar
    • Export Citation
  • 30.

    Harms G, Scherbaum H, Reiter-Owona I, Stitch A, Richter J, 2011. Treatment of imported New World cutaneous leishmaniasis in Germany. Int J Dermatol 50: 13361342.

    • Search Google Scholar
    • Export Citation
  • 31.

    Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzocji MC, Andrade CA, 2011. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118: 8796.

    • Search Google Scholar
    • Export Citation
  • 32.

    Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E, 2011. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venerol 25: 973977.

    • Search Google Scholar
    • Export Citation
  • 33.

    Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC, 2011. Short report: can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 85: 818819.

    • Search Google Scholar
    • Export Citation
  • 34.

    Mueller M, Balasegaram M, Koummuki Y, Rotmeijer K, Santana MR, Davidson R, 2006. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 58: 811815.

    • Search Google Scholar
    • Export Citation
  • 35.

    Soto J, Rhea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210211.

    • Search Google Scholar
    • Export Citation
  • 36.

    Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.

    • Search Google Scholar
    • Export Citation
  • 37.

    Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E, 2010. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 83: 351356.

    • Search Google Scholar
    • Export Citation
  • 38.

    Chrusciak-Talhari A, Dietze R, Chrusciak-Talhari C, da Silva RM, Yamashita EPG, Penna G, Machado PRL, Talhari S, 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255260.

    • Search Google Scholar
    • Export Citation
  • 39.

    van Thiel PPAM, Leenstra T, Kager PA, de Vries HJ, van Vugt M, van der Meide F, Bart A, Zeegelaar JE, van der Sluis A, Schallig HDFH, van Gool T, Faber WR, de Vries PJ, 2010. Miltefosine teatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 50: 8083.

    • Search Google Scholar
    • Export Citation
  • 40.

    Rahman SB, Bari AU, Mumtaz N, 2007. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 17: 132135.

  • 41.

    Figuero RA, Lozano LE, Romero IC, Cardona MT, Prager M, Pacheco R, Diaz YR, Tellez JA, Saravia NG, 2009. Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species. J Infect Dis 200: 638646.

    • Search Google Scholar
    • Export Citation
  • 42.

    Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G, 2003. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36: 560566.

    • Search Google Scholar
    • Export Citation
  • 43.

    Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon I-K, Hummer KA, Gasser RA, Oster CA, Benson PM, 2010. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 4: e628.

    • Search Google Scholar
    • Export Citation
  • 44.

    Bailey MS, Lockwood DNJ, 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203211.

  • 45.

    Ramanathan R, Talaat KR, Fedorko DP, Mahanty S, Nash TE, 2011. A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. Am J Trop Med Hyg 84: 109117.

    • Search Google Scholar
    • Export Citation
  • 46.

    Murray HW, 2004. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2: 279292.

    • Search Google Scholar
    • Export Citation
  • 47.

    Ritmeijer K, Ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN, 2011. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152e158.

    • Search Google Scholar
    • Export Citation
  • 48.

    Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP, 2011. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

Leishmaniasis in the United States: Treatment in 2012

View More View Less
  • Department of Medicine, Weill Cornell Medical College, New York, New York

Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.

Author Notes

*Address correspondence to Henry W. Murray, Department of Medicine, Weill Cornell Medical College, 1300 York Ave. , New York, NY 10065. E-mail: hwmurray@med.cornell.edu

Financial support: This work was supported by National Institutes of Health Grant 5R01AI083219.

Disclosure: The author received travel support in 2009 from Paladin Labs, the manufacturer of miltefosine, to attend an international conference. This statement is made in the interest of full disclosure and not because the author considers this support to be a conflict of interest.

Author's address: Henry W. Murray, Department of Medicine, Weill Cornell Medical College, New York, NY, E-mail: hwmurray@med.cornell.edu.

Save